Abstract
Purpose
Reports suggest pain is common in head and neck cancer (HNC). However, past studies are limited by small sample sizes and design and measurement heterogeneity. Using data from the Head and Neck 5000 longitudinal cohort, we investigated pain over a year post-diagnosis. We assessed: temporal trends; compared pain across HNC treatments, stages, sites and by HPV status; and identified subgroups of patients at increased risk of pain.
Methods
Sociodemographic and clinical data and patient-reported pain (measured by EORTC QLQ-C30 and QLQ-H&N35) were collected at baseline (pre-treatment), 4- and 12- months. Using mixed effects multivariable regression, we investigated time trends and identified associations between (i) clinically-important general pain and (ii) HN-specific pain and clinical, socio-economic, and demographic variables.
Results
2,870 patients were included. At baseline, 40.9% had clinically-important general pain, rising to 47.6% at 4-months and declining to 35.5% at 12-months. HN-specific pain followed a similar pattern (mean score (sd): baseline 26.4 (25.10); 4-months. 28.9 (26.55); 12-months, 17.2 (19.83)). Across time, general and HN-specific pain levels were increased in: younger patients, smokers, and those with depression and comorbidities at baseline, and more advanced, oral cavity and HPV negative cancers.
Conclusions
There is high prevalence of general pain in people living with HNC. We identified subgroups more often reporting general and HN-specific pain towards whom interventions could be targeted.
Implications for cancer survivors
Greater emphasis should be placed on identifying and treating pain in HNC. Systematic pain screening could help identify those who could benefit from an early pain management plan.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Head and neck cancer (HNC) is the sixth most common cancer worldwide with a range of challenges related to high burden of disease, late presentation, and poor access to care [1, 2]. Rising incidence has been reported internationally, attributed to human papilloma virus (HPV) infection. While HPV-positive tumours most commonly occur in the oropharynx, some oral cavity and larynx cancers are also HPV-positive [3]. Recent advances in HNC treatment have improved long-term patient survival and the number of people living with and beyond this cancer. This, in turn, has increased the scope for, and interest in, measuring functional and quality of life (QoL) related outcomes in survivors [4]. QoL has been shown to be an independent prognostic factor for survival in many types of cancer, including HNC, which has further emphasised its importance [5, 6].
Pain is a presenting symptom for up to 70% of patients diagnosed with HNC [7]. The head and neck contains many anatomical structures in a confined space with a significant degree of nerve innervation [8]. As the cancer progresses, these nerves become directly stimulated by the tumours and become prone to perineural invasion (PNI) by the HNC, and many of the proteins and genes implicated in PNI are the same proteins involved in pain signalling [9, 10]. Pain experienced by HNC patients is heterogenous and includes spontaneous pain, function-evoked pain, referred pain, widespread pain, and pain suggestive of peripheral neuropathy [10]. Various factors have been shown to impact pain, including the extent of PNI and metastases, tumour size, location, and stage.
Pain can also be a side-effect of HNC treatment. Surgery can lead to neuropathic pain via direct nerve transection. Lymph node dissection in particular, often leads to the unavoidable cutting of sensory nerve branches [11]. Surgery can also lead to chronic pain due to muscle imbalances resulting from the removal of neck muscles [12, 13]. Non-surgical treatments can be responsible for pain; for instance radiotherapy can lead to osteoradionecrosis, or xerostomia, and although not specific to HNC, chemotherapy can result in peripheral neuropathy and mucositis [14, 15].
Cancer-related pain has an important impact on the lives of people with HNC. The pain itself affects basic functions such as eating and swallowing, as well as interpersonal relations while ineffective control correlates with decreased QoL and poor outcomes [1, 16, 17]. Patients with HNC are prescribed opioids more often than those with other cancers, which comes with significant side-effects and risk for dependence [10, 18].
Despite this, the overall prevalence of pain in HNC, and the factors associated with it, are unclear. Most studies are limited by small sample sizes and cross-sectional designs and, although a range of patients characteristics and other factors have been studied for associations with pain, some studies include individuals treated two decades ago and/or include those with cancer at a specific (sub)site within the head and neck [19,20,21]. The treatment landscape of HNC has also changed dramatically with wider use of minimally invasive surgical techniques, more-precisely targeted radiotherapy and chemotherapy agents with fewer toxic side-effects [22]. Longitudinal studies are limited, so temporal trends are unclear. Furthermore, there is no consistent measurement of pain; for example, some studies report general pain and others HN-specific pain.
Using data from the Head and Neck 5000 (HN5000) prospective, longitudinal, cohort study, we investigated the prevalence of cancer pain (both clinically-important general pain and HN-specific pain) over the first 12 months post-diagnosis. Our objectives were to: (1) assess temporal trends; (2) compare pain across HNC treatments, stages and sites, and by HPV status; and (3) identify subgroups at higher risk of developing pain.
Materials & methods
Study population
The HN5000 protocol and population has been described elsewhere [23, 24]. Participants in the study included individuals aged 16 and older with a new primary or suspected HNC from 76 UK centres. The clinical teams at sites excluded individuals who lacked the capacity to give consent or who they felt were too vulnerable to take part in the study.
In the dataset (version 2.1) utilised for the analysis, 5,404 people who consented to participate between April 2011 and December 2014 were included. In our analysis, we only included individuals who had been diagnosed with cancers of the thyroid, salivary gland, hypopharynx, oropharynx, larynx, and/or oral cavity, undergone treatment, and were free of recurrence during follow-up (N = 3,779). The small sample of patients with hypopharyngeal cancers were combined with laryngeal cancers for analysis. The full breakdown of the study population can be seen in the flow diagram in Supplementary Fig. 1.
Procedures
Participants completed a series of questionnaires focusing on health and lifestyle at baseline (shortly after diagnosis but before treatment started), 4 months, and 12 months. The baseline survey included socio-demographic (e.g., income, marital status) and lifestyle (e.g., smoking, alcohol consumption) characteristics and included the EORTC-QLQ-C30 [25], the EORTC-H&N35 [26] and the Hospital Anxiety & Depression Scale (HADS), a validated screening tool for anxiety and depression [27].
A range of information was abstracted from participants’ medical records. This included demographic characteristics such as age and sex, the ICD10 tumour site [28], TNM-stage [29], laterality of primary tumour and serological human papilloma virus (HPV) status at baseline (which was defined as positive where HPV16E6 was > 1000 median fluorescence intensity) [30]. Treatment received by 4 months was also abstracted as well as the information on whether the tumour had recurred by 4 months or 12 months.
The Adult Comorbidity Evaluation (ACE-27) [31] was used to assign a comorbidity status to each participant. A deprivation category was also assigned to each participant’s home address at baseline, based on the English Index of Multiple Deprivation 2010 [32]. Significant depression was defined with a score of ≥ 8 on the HADS depression subscale, following recommendations for detecting depression in people with cancer [33].
Outcome variables – clinically-important general pain and HN-specific pain
Our study focused on two outcome variables: (i) clinically-important general pain measured using the EORTC-QLQ-C30 and (ii) HN-specific pain measured using the EORTC-QLQ-H&N35. The QLQ-C30 pain subscale includes two questions on general pain (had pain; pain interfered with daily activities) and the H&N35 pain subscale contains four questions focusing more on the head and neck (had pain in the mouth, jaw or throat; had soreness in the mouth), with both questionnaires focusing on pain experienced over the last week. For both subscales, questions were linearly transformed into a score ranging from 0 to 100, with higher scores representing more severe pain. Missing data was treated as recommended by the questionnaire developers [25, 26].
For the QLQ-C30 pain subscale, a score of over ≥ 25/100 indicates the presence of clinically-important pain [34]. We created a binary variable that indicated the presence or absence of clinically-important general pain based on the QLQ-C30 subscale score; the HN-specific pain subscale was treated as a continuous outcome variable.
Statistical analysis
To be included in relevant analyses, patients had to have completed either the QLQ-C30 pain subscale or the HN-specific pain subscale at baseline (Supplementary Fig. 1). Within the study population (n = 3,779), we compared characteristics of those who did, and did not, complete these subscales using chi-square tests.
Amongst those included in analyses, we assessed and compared the proportions with clinically-important general pain and mean scores for HN-specific pain at baseline, 4 months, and 12 months by clinical and socio-demographic characteristics. We used mixed-effects multivariable regression (logistic for general pain, linear for HN-specific pain) to examine temporal trends and factors associated with pain over time. These models allowed us to include all surveys completed by an individual, account for correlations between subjects, and produce robust estimates of error [35].
The following model fitting process was followed first for general pain and then repeated for HN-specific pain. We first examined bivariate associations between candidate predictor variables (socio-demographic, lifestyle and clinical variables (Supplementary Tables 2 and 3)) and the outcome, adjusted for time point. Time point and variables significant at the 5% level were then included in the initial model. Covariables no longer significant at the 5% level in this initial model (assessed using Wald statistics) were then removed. We used Akaike’s Information Criterion (AIC) to compare models with random intercept and random slope with those including random intercept only. Due to the minimal difference between the models, we fitted the least complex option – random intercept with structured covariance. If < 2% of individuals had missing data for a variable, the data was excluded. If the level of missing data was ≥ 2%, an “unknown” category was added to the variable and included in analyses. STATA 17.0 was used for the analysis.
Results
Participants
We included 2,870 and 2,855 patients in the general pain and HN-specific pain analyses respectively (Supplementary Fig. 1). There were no differences in age, treatment, tumour site and laterality between those who completed the baseline questionnaire pain subscales and those who did not. There were statistically significant differences in deprivation, comorbidities, and cancer stage; our analysis included fewer deprived and comorbid patients, as well as fewer patients with higher stage cancers.
The demographic characteristics of individuals included in the analyses can be seen in Supplementary Table 1. Of the people included in the analysis datasets, almost two-thirds were male, just over a quarter had stage 1 disease, and almost half had had multimodal treatment. Almost 90% had cancers in the oropharynx (39%), oral cavity (25%) or larynx (25%), sites at which HPV-positive tumours may occur; overall, 61% of patients had HPV-positive disease.
General pain at each time point
At baseline, 40.9% of patients experienced clinically-important general pain. This figure rose to 47.6% at 4 months and declined to 35.5% (below baseline) at 12 months (Table 1).
By cancer site, at baseline (pre-treatment) the highest prevalence of pain was in patients with oral cavity cancers (48.3%) and the lowest prevalence in thyroid cancer (26.3%). At 4 months, patients with oral cavity cancer experienced slightly less pain (47.3%), whereas all other cancers saw an increase in pain, with over half (53.4%) of oropharyngeal cancer patients experiencing clinically-important pain. At 12 months, every group saw a decline in pain levels with oral, oropharyngeal, and thyroid cancers falling to slightly below baseline levels (38.1%, 34.4% and 24.8% respectively).
Examining pain prevalence by treatment received by 4 months, showed that over half of patients who had multimodal treatment were experiencing clinically-important pain (chemoradiotherapy, 52.6%; surgery with radiotherapy, 57.0%; surgery with chemoradiotherapy, 57.0%) compared to slightly fewer among those who had a single treatment modality. At 12 months, the treatment groups varied relatively little in prevalence. Those diagnosed with stage IV disease had the highest prevalence of pain at all time points. Patterns of prevalence by HPV status varied over time.
The prevalence of clinically-important pain by other socio-demographic, lifestyle and clinical factors at each time point can be seen in Supplementary Table 2. Prevalence was slightly higher in women at each time point, but differences did not reach statistical significance.
HN-specific pain at each time point
The mean scores followed a similar pattern to general pain, namely an increase from baseline to 4 months (26.39 [standard deviation (SD) 25.10] to 28.89 [SD 26.55]), which was then followed by a decrease to below baseline at 12 months (17.24 [SD 19.83]) (Table 2).
Examining the cohort by HN-specific pain showed similar results and followed largely the same pattern as clinically-important general pain by site, stage, treatment and HPV status. The mean HN-specific pain score was significantly higher in women at 12 months, but not at earlier time points. Mean scores for other clinical and socio-demographic characteristics are summarised in Supplementary Table 3.
Factors associated with clinically-important pain over time
In the multivariable mixed logistic regression model, the odds of having clinically-important pain were 26% lower at 12 months than at baseline (OR = 0.74, 95%CI 0.64 to 0.87) (Table 3).
Over 12-months follow-up, increased age reduced the odds of clinically-important pain, with those over 65 years old having 46% lower odds (OR = 0.54, 95%CI 0.40 to 0.73) compared to those under 50. Those living in more (versus least) deprived communities had 2.17 higher odds (OR = 2.17, 95%CI 1.59 to 2.96).
In terms of lifestyle factors, current smokers at baseline had 67% increased odds (OR = 1.67, 95%CI 1.22 to 2.29) of having clinically-important pain compared to those who never smoked; alcohol intake did not increase the odds of having pain when adjusted for other factors.
In terms of clinical variables, depression at baseline was associated with 8.12-fold increase (OR = 8.12, 95%CI 6.23 to 10.57) of having clinically-important pain. For comorbidity, those with moderate or severe decompensation had an OR of 3.38 (95%CI 2.59 to 4.41) compared to those with no comorbidities.
For cancer-related variables, the odds of clinically-important pain were higher in those with stage 2, 3 or 4 disease compared to stage 1, with stage 4 having 92% increased odds compared to stage 1 disease (OR = 1.92, 95%CI 1.47 to 2.50). Those with oral cavity cancer had the highest odds of clinically-important pain compared with other cancers, and thyroid, and larynx/hypopharynx cancer had the lowest odds (OR = 0.35, 95%CI 0.23 to 0.54 and OR = 0.55, 95%CI 0.43 to 0.72 respectively). Participants with HPV positive cancers had 38% lower odds of experiencing clinically-important pain (OR = 0.62, 95%CI 0.46 to 0.83).
Factors associated with HN-specific pain over time
In the multivariable model, the HN-specific pain scores increased significantly at 4 months (Coef = 2.57, 95%CI 1.36 to 3.78) and decreased to below baseline levels at 12 months (Coef=-9.32, 95%CI -10.56 to -8.06) (Table 4).
Over the 12 months follow-up, patients under 50 experienced the highest levels of HN-specific pain and scores decreased with increased age. Current smokers scored 7.07 points (95%CI 5.32 to 8.82) higher on the HN-specific pain scale than non-smokers.
Those with depression scored 12.28 (95%CI 10.89 to 13.66) points higher for HN-specific pain than those without depression. Individuals with moderate or severe decompensation scored 5.56 (95%CI 3.85 to 7.25) higher than those with no comorbidities.
Several cancer-related variables also impacted the HN-specific pain scores. Scores were highest in individuals with stage 4 disease when compared with stage 1 tumours (Coef = 5.55, 95%CI 3.85 to 7.25). Those with oral cavity cancer scored highest compared to other types of HNC; thyroid, laryngeal and hypopharynx cancer patients had the lowest scores (Coef=-15.71, 95%CI -18.09 to -13.33 and − 13.39, 95%CI -15.20 to -11.59 respectively). In terms of treatment, participants who only had surgery had the lowest pain scores, while those who underwent multimodal treatment scored higher. Compared with surgery alone, the surgery combined with radiotherapy group scored 10.91 (95%CI 8.33 to 13.49) higher and the chemoradiotherapy group scored 8.40 points (95% CI 5.53 to 11.26) higher. Participants with HPV positive tumours scored 2.60 points lower (95%CI -4.57 to -1.15) than those with HPV negative tumours.
Discussion
This study is the first large-scale longitudinal investigation of both clinically-important general pain and HN-specific pain in HNC patients and predictors of this pain over time. For both pain outcomes, we found that cancer-related factors such as tumour stage, tumour site, HPV status and treatment were associated with pain over 12 months. Younger age, depression, deprivation, smoking, and comorbidities also had an association with higher levels of pain.
Temporal trends in pain
One of the key findings was the high prevalence of general pain in HNC; the percentage reporting clinically-important pain was high at baseline (41%), increased to almost half (48%) at 4 months, then declined, but only to 36%, at 12 months. HN-specific pain scores also followed a similar pattern. For both outcomes, the 12-month levels were lower than at baseline, but they were still high. The baseline prevalence could, perhaps, be explained by the aetiology of the pain in HNC and the location of the tumour. Baseline pain in HNC may be related to tumour invasion of the bones and soft tissues, benign inflammation, superimposed infections, or due to direct nerve involvement [8]. In many cancers, systemic inflammatory response has been demonstrated to upregulate the innate immune response, which in turn causes a systemic inflammatory response thus resulting in more significant levels of pain [36]. Head and neck squamous cell carcinomas are the most common type of HNC, and they are highly inflammatory and aggressive tumours, which could be contributing to the high levels of pain these patients experience [37, 38].
Our findings of high pain levels at 4 months are consistent with other studies [7, 39] and are likely explained by proximity to treatment, especially in those who received multi-modal treatments. Notably chemo- and radiotherapy are associated with pro-inflammatory cytokines and a systemic inflammatory reaction, thus increasing a pain response [40].
The relative reduction in pain at 12 months, is, perhaps, explained by the reduction of tumour-related pain factors such as inflammation or direct nerve involvement [8]. Our findings appear to contradict a 2010 systematic review which suggested pain does not return to baseline levels and may be higher post- than pre-treatment [39]. However, the studies included in that review had comparatively small sample sizes (N = 20 to 357), and varying times from diagnosis (and baseline) to treatment.
Clinical predictors of pain
Patients having multimodal treatment had significantly higher HN-specific pain scores compared to those who had surgery alone. This is consistent with previous reports [7, 39] and could be explained by the combined side-effects of multiple treatments (e.g., the combination of radiotherapy-induced oral mucositis, damage to sensory nerves in the region during surgery, or increased rates of infections or peripheral neuropathy following chemotherapy). Interestingly, this pattern was not seen on the general pain scale, although it is possible that patients may have experience general pain, but not at a level meeting the threshold for clinical importance.
There are mixed reports of the impact of cancer stage on pain [7, 15]. Our study found that patients with advanced disease at diagnosis had increased odds of both clinically-important general pain and higher HN-specific pain scores. Advanced disease stage indicates either a larger tumour and/or local metastatic disease. Lymph node metastases and large head and neck tumours can impinge on adjacent tissues, obstruct blood vessels, and increase tumour-induced cytokines, activating visceral or somatic nociceptors, thus leading to increased levels of pain [1, 10].
Participants with oral cavity cancer had the highest odds of clinically-important general pain and HN-specific pain scores, and patients with thyroid and larynx/hypopharynx cancer had the lowest odds and scores. This is consistent with smaller, cross-sectional studies [1, 7]. Higher levels of oral cavity cancer pain could partially be explained by the greater prevalence of oral mucosal damage, due to both the disease and its treatment [41, 42].
We also found that patients with HPV positive tumours reported lower pain scores compared to patients with HPV negative tumours, after adjusting for other cancer-related variables. This appears to be a novel finding and explanations are not obvious. Previous studies found that HPV positive tumours more commonly presented with neck mass rather than pain [43]. However, HPV can infect the stratified squamous epithelia in the mouth, throat, and respiratory tract [44]; this, in turn, could affect the nociceptors that have been found to play a role in HNC pain perception [1]. Another possibility is that the finding is driven by inflammation. Xiao et al. reported higher levels of systemic inflammation (measured by C-reactive protein, soluble tumour necrosis factor receptor-2, and interleukin-6 protein) in patients with tumours not related to HPV [45].
Other predictors of pain
We identified several other pain predictors in this study. The strongest relationship was identified in patients with depression at baseline, who had an 8-fold increase in their odds of having clinically-important pain. This supports findings from some other small studies [46, 47] but contradicts others [48]. Uniquely, our study demonstrates this relationship persists over 12 months after adjusting for other variables. Depression has previously been reported as an independent risk factor for the onset of chronic pain in non-cancer patients, and in a separate study, the prevalence of pain in patients with depression was 59% [49, 50]. Additionally, in oncological patients, Derogatis et al. showed that those with diagnosed psychiatric conditions (including depression) were more likely to report significant pain compared to those with no psychiatric diagnosis [51]. Pain and depression are frequently encountered in clinical practice and their coexistence tends to further aggravate the severity of both disorders [52], which could provide a potential explanation for our findings.
Other non-cancer characteristics that were found to be associated with pain were age, comorbidities, and smoking. While all three variables were fitted simultaneously in the models, they are inter-related in the study population making it hard to be confident that these are truly independent effects. Similar to previous research, younger people (< 50) reported more pain than those aged \(\ge\)65 [7]. Gagliese et al. suggest that younger people with cancer pain are less likely to employ strategies to manage the pain [53]. Others report more frequent cancer pain flares in younger people [54]. The EORTC questionnaires used here focus on pain in the last week and perhaps preferentially capture these flares better than chronic, but more stable, pain. Contrary to previous reports [55,56,57], we identified a relationship between comorbidity and increased pain, assessed using the ACE-27 scoring system. The ACE-27 covers a broad range of conditions, and it is unclear whether specific co-morbidities might contribute to the pain reported. Others have suggested a relationship between smoking and pain [14, 58] and our results demonstrate that this persists over 12 months. In terms of other lifestyle factors, in univariable analyses, more frequent alcohol consumption was associated with lower prevalence of clinically-important general pain; while this association no long reached statistical significance in the multivariable model, it is intriguing. Others have reported insufficient pain control in people with cancer [59] and it is possible that our univariable findings reflect use of alcohol to self-medicate for uncontrolled cancer pain.
Implications
These findings show that a significant proportion of HNC patients suffer from pain at diagnosis and after treatment; it seems likely that this, in turn, has a substantial impact on QoL.
The high burden of pain in HNC patients with depression is particularly concerning, and clinical teams should put a greater emphasis on both diagnosis and treatment of depression in this population. Screening questionnaires for depression, such as the HADS, could be used more frequently and HNC multi-disciplinary teams could be expended to include clinical psychologists more routinely.
Systematic pain screening could also help to identify who could benefit from a pain management plan at an earlier stage. Appropriate analgesia should be a priority, and Ren et al. [47] have previously shown that while 11.6% of patients with HNC reported neuropathic pain, only 3.8% were taking psychotropic medications targeting this kind of pain. It is therefore important for clinicians to identify the type of pain these patients experience and prescribe their analgesia accordingly.
Other, non-medical strategies for pain control should also be utilised, such as complementary therapies [60]. Several studies have shown that physical activity significantly improves specific HNC-related pain [61,62,63]. Larger scale randomised studies of interventions to encourage and support physical activity are warranted to explore the potential improvements in QoL and pain in this patient group.
Strengths and limitations
There was wide variability in the reporting of prevalence of cancer pain in HNC patients in previous studies; a 2012 systematic review reported prevalence ranged from 9 to 98% [7]. This variability is caused by a number of issues, including variations in: study design; distributions of age, primary site, and stages of included patients; treatment modalities received; definition of pain used; and method(s) of pain evaluation. The review highlighted the need for high quality epidemiological studies. In response, we conducted the largest cohort study to date and reported on pre- and post- treatment HNC pain. We used two EORTC instruments to capture both general and HN-specific pain, reported descriptive data on pain levels in different patient subgroups, and applied robust statistical methods to investigate trends and associations.
There are some limitations to our study. Although widely used, the pain subscales contain only two general and four HN-specific questions, and it is possible these do not capture all manifestations of pain in HNC patients. It is also worth noting that the instruments only capture pain experienced in the last week. Moreover, it is difficult to determine whether the patients’ pain is fully due to the cancer or other non-cancer causes (e.g., arthritis or other comorbid conditions).
The overall prevalence of general pain and HN-specific pain scores are also likely underestimated in our analysis. Patients with more advanced cancer – which was associated here with more pain - were underrepresented in the HN5000 cohort, and our study population.
Conclusions
Over a third of HNC patients experience clinically-important pain at 12 months post-diagnosis. Socio-demographic, cancer-specific, and other clinical variables predicted likelihood of clinically-important general pain and HN-specific pain scores over 12 months. These findings show that there is a need for additional interventions focusing on addressing this problem before, during and after cancer treatment.
Data availability
The data that support the findings of this study are available from Head and Neck 5000. Further information may be found on the Head and Neck 5000 website: https://www.headandneck5000.org.uk/ information-for-researchers.
References
Reyes-Gibby CC, Anderson KO, Merriman KW, Todd KH, Shete SS, Hanna EY. Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. J Pain. 2014;15(10):1015–22. https://doi.org/10.1200/edbk_320923.
Fagan JJ, Noronha V, Graboyes EM. Making the best of Limited resources: improving outcomes in Head and Neck Cancer. Am Soc Clin Oncol Educ Book. 2021;41:1–11. https://doi.org/10.1200/edbk_320923.
Roman BR, Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck. J Surg Oncol. 2021;124(6):920–2. https://doi.org/10.1002%2Fjso.26687.
Riechelmann H, Dejaco D, Steinbichler TB, et al. Functional outcomes in Head and Neck Cancer patients. Cancers (Basel). 2022;14(9):2135. https://doi.org/10.3390%2Fcancers14092135.
Husson O, de Rooij BH, Kieffer J, et al. The EORTC QLQ-C30 Summary score as prognostic factor for survival of patients with Cancer in the Real-World: results from the Population-based PROFILES Registry. Oncologist. 2020;25(4):e722–32. https://doi.org/10.1634/theoncologist.2019-0348.
Rogers SN, Waylen AE, Thomas S, et al. Quality of life, cognitive, physical and emotional function at diagnosis predicts head and neck cancer survival: analysis of cases from the Head and Neck 5000 study. Eur Arch Otorhinolaryngol. 2020;277(5):1515–23. https://doi.org/10.1007/s00405-020-05850-x.
Macfarlane TV, Wirth T, Ranasinghe S, Ah-See KW, Renny N, Hurman D. Head and neck cancer pain: systematic review of prevalence and associated factors. J Oral Maxillofac Res. 2012;3(1):e1. https://doi.org/10.5037/jomr.2012.3101.
Chua KS, Reddy SK, Lee MC, Patt RB. Pain and loss of function in head and neck cancer survivors. J Pain Symptom Manage. 1999;18(3):193–202. https://doi.org/10.1016/s0885-3924(99)00070-6.
Saidak Z, Lailler C, Clatot F, Galmiche A. Perineural invasion in head and neck squamous cell carcinoma: background, mechanisms, and prognostic implications. Curr Opin Otolaryngol Head Neck Surg. 2020;28(2):90–5. https://doi.org/10.1097/moo.0000000000000610.
Ye Y, Jensen DD, Viet CT, et al. Advances in Head and Neck Cancer Pain. J Dent Res. 2022;101(9):1025–33. https://doi.org/10.1177/00220345221088527.
Vecht CJ, Hoff AM, Kansen PJ, de Boer MF, Bosch DA. Types and causes of pain in cancer of the head and neck. Cancer. 1992;70(1):178–84. https://doi.org/10.1002/1097-0142(19920701)70:1%3C178. ::aid-cncr2820700128%3E3.0.co;2-e.
Talmi YP, Horowitz Z, Pfeffer MR, et al. Pain in the neck after neck dissection. Otolaryngol Head Neck Surg. 2000;123(3):302–6. https://doi.org/10.1067/mhn.2000.104946.
Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope. 2008;118(2):300–6. https://doi.org/10.1097/mlg.0b013e31815a9ed3.
Logan HL, Fillingim RB, Bartoshuk LM, et al. Smoking status and pain level among head and neck cancer patients. J Pain. 2010;11(6):528–34. https://doi.org/10.1016/j.jpain.2009.09.006.
Cramer JD, Johnson JT, Nilsen ML. Pain in Head and Neck Cancer survivors: Prevalence, Predictors, and Quality-of-life impact. Otolaryngol Head Neck Surg. 2018;159(5):853–8. https://doi.org/10.1177/0194599818783964.
Nayak SG, Pai MS, George LS. Quality of life of patients with head and neck cancer: a mixed method study. J Cancer Res Ther. 2019;15(3):638–44. https://doi.org/10.4103/jcrt.jcrt_1123_16.
Viet CT, Schmidt BL. Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res. 2012;91(5):447–53. https://doi.org/10.1177/0022034511424156.
Sethi RKV, Panth N, Puram SV, Varvares MA. Opioid prescription patterns among patients with Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(4):382–3. https://doi.org/10.1001/jamaoto.2017.3343.
Cuffari L, Tesseroli de Siqueira JT, Nemr K, Rapaport A. Pain complaint as the first symptom of oral cancer: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(1):56–61. https://doi.org/10.1016/j.tripleo.2005.10.041.
Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(5):546–52. https://doi.org/10.1016/j.tripleo.2003.12.041.
Jainkittivong A, Swasdison S, Thangpisityotin M, Langlais RP. Oral squamous cell carcinoma: a clinicopathological study of 342 Thai cases. J Contemp Dent Pract. 2009;10(5):E033–E40.
Cramer JD, Burtness B, Le Q, et al. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16:669–83. https://doi.org/10.1038/s41571-019-0227-z.
Ness AR, Waylen A, Hurley K, et al. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014;14:973. https://doi.org/10.1186/1471-2407-14-973.
Ness AR, Waylen A, Hurley K, et al. Recruitment, response rates and characteristics of 5511 people enrolled in a prospective clinical cohort study: head and neck 5000. Clin Otolaryngol. 2016;41(6):804–9. https://doi.org/10.1111/coa.12548.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. https://doi.org/10.1093/jnci/85.5.365.
Hammerlid E, Adnan A, Silander E. Population-based reference values for the European Organization for Research and Treatment of Cancer Head and Neck module. Head Neck. 2017;39(10):2036–47. https://doi.org/10.1002/hed.24870.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x.
World Health Organisation. International Statistical Classification of Diseases and Related Health Problems. 2010, Available from https://www.who.int/publications/m/item/international-statistical-classification-of-diseases-and-related-health-problems---volume-2 [Accessed 04/10/2023].
Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31(21):2708–15. https://doi.org/10.1200/jco.2012.47.2738.
Royal College of Physicians. Adult Co-morbidity Evaluation‐27. https://www.rcplondon.ac.uk/file/3058/download [Accessed 04/10/2023].
Ministry of Housing, Communities and Local Government. Engl Indices Deprivation, 2010. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010 [Accessed 04/10/2023].
Annunziata MA, Muzzatti B, Bidoli E, et al. Hospital anxiety and Depression Scale (HADS) accuracy in cancer patients. Support Care Cancer. 2020;28(8):3921–6. https://doi.org/10.1007/s00520-019-05244-8.
Giesinger JM, Kuijpers W, Young T, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 2016;14:87. https://doi.org/10.1186/s12955-016-0489-4.
Brown H, Prescott R. Applied mixed models in Medicine, in statistics in Practice. John Wiley & Sons, West Sussex UK; 2006.
Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25. https://doi.org/10.1002/cncr.11382.
Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol. 2009;9(4):389–95. https://doi.org/10.1016/j.coph.2009.06.005.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma [published correction appears in Nat Rev Dis Primers. 2023;9(1):4]. Nat Rev Dis Primers. 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3.
Epstein JB, Hong C, Logan RM, et al. A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer. 2010;18(8):1023–31. https://doi.org/10.1007/s00520-010-0897-7.
Bossi P, Ghiani M, Argenone A, Depenni R. Is pain part of a systemic syndrome in head and neck cancer? Support Care Cancer. 2020;28(2):451–9. https://doi.org/10.1007/s00520-019-05147-8.
Rodríguez-Fuentes ME, Pérez-Sayáns M, Carreras-Presas CM, Marichalar-Mendia X, Bagán-Debón L, López-López R. Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;135(3):385–95. https://doi.org/10.1016/j.oooo.2022.11.016.
Khawaja SN, Jamshed A, Hussain RT. Prevalence of pain in oral cancer: a retrospective study. Oral Dis. 2021;27(7):1806–12. https://doi.org/10.1111/odi.13701.
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(5):441–7. https://doi.org/10.1001/jamaoto.2014.141.
Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122(3):306–14. https://doi.org/10.1038/s41416-019-0602-7.
Xiao C, Beitler JJ, Higgins KA, et al. Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer. Cancer. 2018;124(15):3163–70. https://doi.org/10.1002/cncr.31537.
Zwahlen RA, Dannemann C, Grätz KW, et al. Quality of life and psychiatric morbidity in patientssuccessfully treated for oral cavity squamous cell cancer and their wives. J Oral Maxillofac Surg. 2008;66(6):1125–32. https://doi.org/10.1016/j.joms.2007.09.003.
Ren JL, Rojo RD, Perez JVD, Yeung SJ, Hanna EY, Reyes-Gibby CC. Variations in pain prevalence, severity, and analgesic use by duration of survivorship: a cross-sectional study of 505 post-treatment head and neck cancer survivors. BMC Cancer. 2021;21(1):1304. https://doi.org/10.1186/s12885-021-09024-8.
Chan JY, Lua LL, Starmer HH, Sun DQ, Rosenblatt ES, Gourin CG. The relationship between depressive symptoms and initial quality of life and function in head and neck cancer. Laryngoscope. 2011;121(6):1212–8. https://doi.org/10.1002/lary.21788.
Agüera-Ortiz L, Failde I, Mico JA, Cervilla J, López-Ibor JJ. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. J Affect Disord. 2011;130(1–2):106–12. https://doi.org/10.1016/j.jad.2010.10.022.
Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast. 2015;2015:504691. https://doi.org/10.1155/2015/504691.
Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249(6):751–7. https://doi.org/10.1001/jama.249.6.751.
Sheng J, Liu S, Wang Y, Cui R, Zhang X. The link between Depression and Chronic Pain: neural mechanisms in the brain. Neural Plast. https://doi.org/10.1155/2017/9724371.
Gagliese L, Jovellanos M, Zimmermann C, Shobbrook C, Warr D, Rodin G. Age-related patterns in adaptation to cancer pain: a mixed-method study. Pain Med. 2009;10(6):1050–61. https://doi.org/10.1111/j.1526-4637.2009.00649.x.
Green CR, Hart-Johnson T. Cancer pain: an age-based analysis. Pain Med. 2010;11(10):1525–36. https://doi.org/10.1111/j.1526-4637.2010.00957.x.
Dugué J, Humbert M, Bendiane MK, Bouhnik AD, Babin E, Licaj I. Head and neck cancer survivors’ pain in France: the VICAN study. J Cancer Surviv. 2022;16(1):119–31. https://doi.org/10.1007/s11764-021-01010-0.
Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E, Conroy T. Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(3):742–51. https://doi.org/10.1016/s0360-3016(02)02959-0.
Smit M, Balm AJ, Hilgers FJ, Tan IB. Pain as sign of recurrent disease in head and neck squamous cell carcinoma. Head Neck. 2001;23(5):372–5. https://doi.org/10.1002/hed.1046.
Shuman AG, Terrell JE, Light E, et al. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(12):1147–54. https://doi.org/10.1001/jamaoto.2013.853.
Scarborough B, Cardinale CB. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin. 2018;68(3):182–96. https://doi.org/10.3322/caac.21453.
Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ. Psychological and behavioral approaches to cancer pain management. J Clin Oncol. 2014;32(16):1703–11. https://doi.org/10.1200/jco.2013.54.4825.
McNeely ML, Parliament MB, Seikaly H, et al. Effect of exercise on upper extremity pain and dysfunction in head and neck cancer survivors: a randomized controlled trial. Cancer. 2008;113(1):214–22. https://doi.org/10.1002/cncr.23536.
Su TL, Chen AN, Leong CP, et al. The effect of home-based program and outpatient physical therapy in patients with head and neck cancer: a randomized, controlled trial. Oral Oncol. 2017;74:130–4. https://doi.org/10.1016/j.oraloncology.2017.10.002.
Karlsson O, Karlsson T, Pauli N, Andréll P, Finizia C. Jaw exercise therapy for the treatment of trismus in head and neck Cancer: a prospective three-year follow-up study. Support Care Cancer. 2021;29(7):3793–800. https://doi.org/10.1007/s00520-020-05517-7.
Funding
This publication presents data from the Head and Neck 5000 study. The study was a component of independent research funded by the National Institute for Health and Care Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG‐0707‐10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to Professor Andy Ness. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant number: C18281/A19169).
Author information
Authors and Affiliations
Contributions
Conceptualization, LS and JMP; Data curation, KH and SJT; Formal analysis, IB and LS; Funding acquisition, SJT; Resources, SJT; Writing – original draft, IB; Writing – review & editing, IB, LS, LJW, LL, SH, KH, SJT and JMP.
Corresponding author
Ethics declarations
Institutional Review Board Statement
The HN5000 study was approved by the National Research Ethics Committee (South West Frenchay Ethics Committee, reference 10/H0107/57, 5 November 2010), and the Research & Development departments of participating NHS Trusts. The Newcastle University Ethics Committee granted approval for this study (Ref. 13724/2020).
Informed consent Statement
Informed consent was obtained from all patients recruited to HN5000.
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bolnykh, I., Patterson, J.M., Harding, S. et al. Cancer-related pain in head and neck cancer survivors: longitudinal findings from the Head and Neck 5000 clinical cohort. J Cancer Surviv (2024). https://doi.org/10.1007/s11764-024-01554-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11764-024-01554-x